Cost-Effectiveness of Cilostazol,Naftidrofuryl Oxalate,and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease
Restricted accessResearch articleFirst published online March, 2014
Cost-Effectiveness of Cilostazol,Naftidrofuryl Oxalate,and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease
We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management. A Markov decision model was developed to assess the lifetime costs and benefits of each vasoactive drug compared to no vasoactive drug and with each other. Regression analysis was undertaken to model the relationship between maximum walking distance and utility. Resource use data were sourced from the literature and sensitivity analyses were undertaken. Naftidrofuryl oxalate is more effective and less costly than cilostazol and pentoxifylline and has an estimated cost per quality-adjusted life year gained of around £6070 compared to no vasoactive drug. The analysis uses effectiveness evidence from a network meta-analysis. In contrast to previous guidelines recommending cilostazol, the analysis suggests that naftidrofuryl oxalate is the only vasoactive drug for PAD which is likely to be cost-effective.
NorgrenLHiattWRDormandyJA. Inter-society consensus for the management of peripheral arterial disease (TASC II). Intl Angiol. 2007;26(2):82–157.
2.
PellJP.Impact of intermittent claudication on quality of life. The Scottish vascular audit group. Eur J Vasc Endovasc.1995;9(4):469–472.
3.
BreekJCHammingJFDeVJ. Quality of life in patients with intermittent claudication using the World Health Organisation (WHO) questionnaire. Eur J Vasc Endovasc. 2001;21(2):118–122.
4.
FowkesFGRHousleyECawoodE. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20(2):384–392.
5.
SquiresHSimpsonEMengY. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Asses. 2011;15(40):i–210.
6.
GuestJFDavieAMCleggJP. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Curr Med Res Opin. 2005;21(6):817–826.
7.
O'DonnellMEBadgerSASharifMA. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49(5):1226–1234.
8.
KiefferEBahniniAMourenXGamandS. Anew study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol. 2001;20(1):58–65.
9.
HiattWRMoneySRBrassEP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008;47(2):330–336.
10.
Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care 2009. London, England: PSSRU; 2009.
11.
National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London, England: NICE; 2008.
12.
StevensJEmmaSHarnanS. Efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication in patients with peripheral arterial disease: systematic review and evidence synthesis. Br J Surg. 2012;99:1630–1638.
13.
BeebeHGDawsonDLCutlerBS. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159(17):2041–2050.
14.
AraRBrazierJ. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11(7):1131–1143.
15.
AraRBrazierJ. Populating an economic moel with health state utility values: moving towards better practice. Value Health. 2010;13(5):509–518.
16.
O'DonnellMEBadgerSASharifMA. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vasc Endovasc Surg. 2009;43(2):132–143.
17.
DawsonDLCutlerBSHiattWR. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109(7):523–530.
18.
AdhouteGBacourtFBarralM. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg. Angiology. 1986;37(3 pt 1):160–167.
19.
Otsuka Pharmaceutical Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease. 2010.
20.
Office for National Statistics (ONS). Mid-2009 Population Estimates: England and Wales; Estimated Resident Population by Single Year of Age and Sex. London, UK: ONS; 2010.
21.
HealdCLFowkesFGRMurrayGDPriceJF. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. Atherosclerosis. 2006;189(1):61–69.
Department of Health (DoH). NHS Reference Costs 2008-2009. London, UK: DoH; 2010.
24.
Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and Management of Peripheral Arterial Disease. A National Clinical Guideline. Edinburgh, Scotland: SIGN; 2006.
25.
SpengelFClementDBoccalonH. Findings of the naftidrofuryl in quality of life (NIQOL) European study program. Int Angiol. 2002;21(1):20–27.
26.
National Institute for Health and Clinical Excellence (NICE). NICE Technology Appraisal Guidance 223: Cilostazol, Naftidrofuryl Oxalate, Pentoxifylline and Inositol Nicotinate for the Treatment of Intermittent Claudication in People with Peripheral Arterial Disease. London, UK: NICE; 2011.
